Testosterone enanthate side effects

Testosterone Enanthate is a testosterone ester that was synthesized in 1952. It is used to treat hypogonadism, that is, a natural lack of testosterone in the body. It is the most widely used form of testosterone in androgen replacement therapy. Testosterone enanthate is widely used in sports. Introduced into the body by intramuscular injection.
Hypersensitivity to testosterone and its esters, breast cancer (in men), prostate cancer (known or suspected), pregnancy, lactation, use in women who are able to become pregnant.
- for depot testosterone (testosterone cypionate) - serious diseases of the heart, liver or kidneys;
- for testosterone enanthate (s / c) and undecanoate (orally) - use in men with hypogonadal conditions not associated with structural or genetic etiology (for example, age-related hypogonadism).

Side effects of Testosterone enatant.

Abscess at the injection site, acute myocardial infarction, allergic dermatitis, altered hormone levels (fluctuations in testosterone levels), amnesia, anaphylactic shock, anaphylaxis, androgenetic alopecia, angina pectoris, angioedema, asthma, azoospermia, bitter taste, retention heart failure, cerebral infarction, cerebrovascular accident, cerebrovascular insufficiency, changes in HDL levels, pain in the mammary gland, cholestatic jaundice, COPD, circulatory shock, suppression of coagulation factors (factors II, V, VII, X), ischemic heart disease, occlusion of coronary arteries , decreased plasma testosterone levels, decreased thyroxine-binding globulin levels, deep vein thrombosis, diabetes mellitus, sweating, discomfort at the injection site, dizziness, drug abuse, shortness of breath, edema, electrolyte disturbances (calcium, nitrogen, phosphorus, potassium, sodium), erectile dysfunction, fluid retention, flu symptoms, frequent eras lesions, genitourinary infection (prostate), gingival erythema, hair discoloration, hearing loss (sudden), hematoma at the injection site, liver neoplasm, hepatocellular neoplasm, hepatotoxicity, hirsutism, hyperchloremia, hypernatremia, hyperparathyroidism, hypersensitivity angiitis, hyperventilation reaction, increased GGT levels, increased serotoxin glutamyltransferase, serum aspartate aminotransferase, increased serum prolactin levels, increased serum transaminases, increased testosterone levels, infection, injection site reaction, delayed inorganic phosphate, injection site irritation, Korsakov's syndrome (non-alcoholic), lip swelling, focal infection (abscess), cellulitis, malaise, malignant neoplasm of the prostate, migraine, musculoskeletal chest pain, musculoskeletal pain, nephrolithiasis, nipple tenderness (sensitivity), non-immune anaphosylaxis (may occur with high doses), inflammation of the oral cavity, ulcer of the oral mucosa, orgasm disturbance (in men), osteoporosis, papular rash, pelious hepatitis, peripheral venous insufficiency, pharyngeal edema, pain in the pharynx, pollakiuria, potassium retention, priapism, prolonged APTT, prolonged epithelial PT, intra prostate neoplasia, pulmonary embolism (including pulmonary oil microembolism), renal colic, renal impairment, renal pain, respiratory distress, anxiety, reversible ischemic neurological deficits, rhinitis, sleep disturbances, snoring, sodium retention, spermatocele, stomatitis, suicidal thoughts, fainting, SLE, tachycardia, testicular pain, thrombocytopenia, thromboembolism, thrombosis of the upper abdominal arteries, ear pain, transient pain during urination, vasodilation, venous thromboembolism, vitreous detachment, voice disturbance, xerostomia.

Side effects of testosterone enanthate include, among others, virilization. In normal men, approximately 10 percent of testosterone enanthate is converted to dihydrotestosterone. Dihydrotestosterone (DHT) can promote masculinity in both men and women. These male characteristics include clitoral hypertrophy, androgenetic alopecia, body hair growth, and deepening of the vocal cords. DHT also plays an important role in male sexual function and may also be a contributing factor to ischemic priapism in men, as shown in a study using finasteride to treat ischemic priapism in men. Testosterone enanthate can also increase igf-1 and igf-bp. Testosterone enanthate can also be converted to estradiol by aromatase, which can lead to gynecomastia in men. Aromatase inhibitors can help prevent the estrogenic activity of testosterone enanthate in the body.